The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

McN-A-343     4-[(3- chlorophenyl)carbamoyloxy]but- 2-ynyl...

Synonyms: CHEMBL74300, SureCN2977744, CHEBI:218069, AC1L1LFI, LS-18194, ...
This record was replaced with 4022.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lopac-C-7041


Psychiatry related information on Lopac-C-7041

  • Bilateral perfusion with either McN-A-343 (M1 muscarinic) or nicotine (both 10(-5)-10(-3) M) did not have any effect on cataplexy in either narcoleptic or control canines [5].
  • 1. The ability to modify the pain threshold by the two M1-muscarinic agonists: McN-A-343 and AF-102B and by the specific M2-agonist arecaidine was examined in mice and rats by using three different noxious stimuli: chemical (writhing test), thermic (hot-plate test) and mechanical (paw pressure test) [6].
  • The M1 agonist McN-A-343 did not elicit any change in sleep or REM sleep percentage [7].
  • On trial 2 in the elevated plus-maze, a model of specific phobia, the endogenous cholinergic system, nicotine, and the M(1) receptor agonist, McN-A-343, all mediate an anxiolytic effect, whereas stimulation of 5-HT(1A) receptors mediates an anxiogenic effect [8].

High impact information on Lopac-C-7041

  • Moreover, 4-(m-chlorophenyl carbamoyloxy)-2-butyltrimethylammonium chloride (McN-A-343), a muscarinic ganglionic stimulant, also caused relaxation of the lower esophageal sphincter [9].
  • In rabbit vas deferens, the inhibitory effect of the combination of C7/3-phth and atropine on the responses to McN-A-343 at the M1 receptor was more pronounced than that of the combination of C7/3-phth and PZP [10].
  • Selectivity of McN-A-343 in stimulating phosphoinositide hydrolysis mediated by M1 muscarinic receptors [11].
  • In addition, microinjection of ACh (5 pmol) or the muscarinic M1 receptor agonist McN-A-343 (30 ng) into the lateral hypothalamic nucleus increased pancreatic secretion over basal levels by 46 % and 40 %, respectively [12].
  • Islet-activating protein (2 micrograms/2 microliters) treatment alone did not change in vivo striatal dopamine (DA) release and metabolism, but completely abolished the increase of striatal DA release evoked in vivo by the M1-selective agonist McN-A-343 (10(-7) M) [13].

Chemical compound and disease context of Lopac-C-7041

  • Propranolol partially reduced McN-A-343 tachycardia, suggesting catecholamine release [3].
  • In addition, the mechanical hypersensitivity in diabetic mice was reduced by the selective muscarinic M1 receptor agonist McN-A-343 (4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium chloride) (i.t.). These results suggest that spinal muscarinic M1 receptors participate in the antiallodynic effect of clonidine in diabetic mice [14].
  • The dose of PZP used blocked the increase in FLPP and HR evoked by the muscarinic receptor agonist McN-A-343, but not the increase evoked by the nicotinic receptor agonist DMPP, when these drugs were injected into the arterial supply of the ganglion [15].
  • 3. Doses of guanethidine (1 mg/kg) and pentacynium (1 mg/kg) blocking pressor responses to intravenous administration of the ganglion stimulants McN-A-343 and DMPP, respectively, did not affect responses to AA [16].

Biological context of Lopac-C-7041


Anatomical context of Lopac-C-7041

  • The aziridinium ion had 1/4 the potency of McN-A-343 (1) as a ganglionic muscarinic stimulant in the anesthetized, pentolinium-treated rat but showed no muscarinic effects on the isolated guinea pig ileum [21].
  • Two M1-mediated responses elicited by McN-A-343 were studied: relaxation of the isolated rat duodenum and inhibition of twitch contractions in rabbit was deferens [22].
  • The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart [23].
  • The M1-selective compound, pirenzepine (1-30 micrograms kg-1), was a potent antagonist of the McN-A-343 effect, whereas the cardioselective M2-antagonist, AF-DX 116, and the smooth muscle selective compound, 4-diphenylacetoxy-N-methyl piperidine (4-DAMP), were completely ineffective at the doses tested [3].
  • It is postulated that the emesis produced by McN-A-343, injected into the cerebral ventricles, is mediated through muscarinic M1 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)[2]

Associations of Lopac-C-7041 with other chemical compounds


Gene context of Lopac-C-7041

  • ACh and McN-A-343 produced endothelium-dependent dilation that was blocked by 4-diphenyl-N-methyl-piperidine methiodide, an inhibitor of the M3 receptor [28].
  • Pharmacological characterization of the MAPK response revealed that McN-A-343 was a partial agonist at the M1 and M3 subtypes, and that pilocarpine was a partial agonist at the M3 and M5 receptors [29].
  • Forskolin (10(-5) M), an adenylate cyclase activator, increased DA release and showed an additive effect on the DA release evoked by McN-A-343 [13].
  • METHOD: Anxiety was evaluated in the elevated plusmaze and spontaneous working memory was evaluated in the Y-maze following scopolamine, pirenzepine or McN-A-343 infusion in the IL cortex [30].
  • 1. Concentration-effect curves were obtained, in the absence and presence of histamine H2-receptor blockade, to 5-methylfurmethide (5-MeF) and McN-A 343, high efficacy and low efficacy acetylcholine (ACh) M-receptor agonists, respectively, in isolated stomach preparations from the mouse and immature rat and guinea-pig [27].

Analytical, diagnostic and therapeutic context of Lopac-C-7041

  • Topical McN-A-343 (10(-7), 10(-4) M), an M-1 agonist, produced pial arteriolar constriction (diameters were 140 +/- 8, 127 +/- 9 and 111 +/- 8 microns for control, 10(-7) and 10(-4) M McN-A-343) that was blocked by topical pirenzepine (10(-3) M), an M-1 antagonist [31].
  • 3 Close intra-arterial injection of SGTX (6.2-12.3 nmol/kg) to the superior cervical ganglion blocked the contractile response of the nictitating membrane to preganglionic stimulation of cervical sympathetic nerve or injected DMPP, but not to postganglionic stimulation or to injected adrenaline and McN-A-343 [32].
  • Pressure application of McN-A-343 onto isolated DUM neurones induced a dose- and voltage-dependent biphasic response composed of a fast initial hyperpolarization followed by a slow depolarizing phase, recorded with the patch-clamp technique in the whole-cell recording configuration [33].
  • 3. Pressor responses elicited either by electrical stimulation of the spinal sympathetic outflow or by stimulation of sympathetic ganglion cells with the muscarinic agonist McN-A-343 were reduced by DAMA [34].
  • Using the cannula inserting method, we investigated vascular responses to ACh and McN-A-343 (a M1-agonist) in isolated and perfused canine and simian facial veins in non-preconstricted conditions [35].


  1. Calcium-dependent potassium conductance in guinea-pig olfactory cortex neurones in vitro. Constanti, A., Sim, J.A. J. Physiol. (Lond.) (1987) [Pubmed]
  2. Emesis induced by 4-(m-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium chloride (McN-A-343): evidence for a predominant central muscarinic M1 mediation. Beleslin, D.B., Nedelkovski, V. Neuropharmacology (1988) [Pubmed]
  3. Pharmacological characterization of muscarinic receptors involved in McN-A-343-induced effects on intestinal motility and heart rate in conscious dogs. Schiavone, A., Sagrada, A., Micheletti, R., Giachetti, A. Br. J. Pharmacol. (1988) [Pubmed]
  4. Mechanism of the bradycardia produced in the cat by the anticholinesterase neostigmine. Backman, S.B., Bachoo, M., Polosa, C. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  5. Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Reid, M.S., Tafti, M., Nishino, S., Siegel, J.M., Dement, W.C., Mignot, E. Sleep. (1994) [Pubmed]
  6. Role of muscarinic receptor subtypes in central antinociception. Bartolini, A., Ghelardini, C., Fantetti, L., Malcangio, M., Malmberg-Aiello, P., Giotti, A. Br. J. Pharmacol. (1992) [Pubmed]
  7. Effect of specific M1, M2 muscarinic receptor agonists on REM sleep generation. Velazquez-Moctezuma, J., Gillin, J.C., Shiromani, P.J. Brain Res. (1989) [Pubmed]
  8. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. File, S.E., Kenny, P.J., Cheeta, S. Pharmacol. Biochem. Behav. (2000) [Pubmed]
  9. Nature of the vagal inhibitory innervation to the lower esophageal sphincter. Goyal, R.K., Rattan, S. J. Clin. Invest. (1975) [Pubmed]
  10. Assessment of the allosteric interactions of the bisquaternary heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide at M1 and M2 muscarine receptors. Christopoulos, A., Mitchelson, F. Mol. Pharmacol. (1994) [Pubmed]
  11. Selectivity of McN-A-343 in stimulating phosphoinositide hydrolysis mediated by M1 muscarinic receptors. Hu, J.R., el-Fakahany, E.E. Mol. Pharmacol. (1990) [Pubmed]
  12. Hypothalamic regulation of pancreatic secretion is mediated by central cholinergic pathways in the rat. Li, Y., Wu, X., Zhu, J., Yan, J., Owyang, C. J. Physiol. (Lond.) (2003) [Pubmed]
  13. In vivo striatal dopamine release by M1 muscarinic receptors is induced by activation of protein kinase C. Xu, M., Yamamoto, T., Kato, T. J. Neurochem. (1990) [Pubmed]
  14. Intrathecal clonidine inhibits mechanical allodynia via activation of the spinal muscarinic M1 receptor in streptozotocin-induced diabetic mice. Koga, K., Honda, K., Ando, S., Harasawa, I., Kamiya, H.O., Takano, Y. Eur. J. Pharmacol. (2004) [Pubmed]
  15. Pirenzepine-sensitive component of forelimb vascular resistance and heart rate in cats. Stein, R., Bachoo, M., Polosa, C. J. Auton. Nerv. Syst. (1995) [Pubmed]
  16. Sensitivity changes of the perfused hindquarters' vasculature in rats with alloxan-induced diabetes mellitus. Boura, A.L., Hodgson, W.C., King, R.G. Clin. Exp. Pharmacol. Physiol. (1987) [Pubmed]
  17. Actions of vasoactive intestinal polypeptide in superior cervical ganglion of the cat. Machová, J. Neuropharmacology (1987) [Pubmed]
  18. Cardiovascular effects of central administration of cholinomimetics in anesthetized cats. Ally, A., Hara, Y., Murayama, S. Neuropharmacology (1993) [Pubmed]
  19. Muscarinic activity of McN-A-343 and its value in muscarinic receptor classification. Eglen, R.M., Kenny, B.A., Michel, A.D., Whiting, R.L. Br. J. Pharmacol. (1987) [Pubmed]
  20. Characterization of muscarinic receptors mediating vasodilation in guinea-pig ileum submucosal arterioles by the use of computer-assisted videomicroscopy. Bungardt, E., Vockert, E., Feifel, R., Moser, U., Tacke, R., Mutschler, E., Lambrecht, G., Surprenant, A. Eur. J. Pharmacol. (1992) [Pubmed]
  21. Tertiary 2-haloethylamine derivatives of the muscarinic agent McN-A-343, [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride. Ringdahl, B., Mellin, C., Ehlert, F.J., Roch, M., Rice, K.M., Jenden, D.J. J. Med. Chem. (1990) [Pubmed]
  22. Functional determination of McN-A-343 affinity for M1 muscarinic receptors. Micheletti, R., Schiavone, A. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
  23. The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart. Birdsall, N.J., Burgen, A.S., Hulme, E.C., Stockton, J.M., Zigmond, M.J. Br. J. Pharmacol. (1983) [Pubmed]
  24. Pharmacological and functional characterization of muscarinic receptors in the frog pars intermedia. Garnier, M., Lamacz, M., Galas, L., Lenglet, S., Tonon, M.C., Vaudry, H. Endocrinology (1998) [Pubmed]
  25. Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists. Wang, S.Z., el-Fakahany, E.E. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  26. Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release. Vizi, E.S., Kobayashi, O., Töröcsik, A., Kinjo, M., Nagashima, H., Manabe, N., Goldiner, P.L., Potter, P.E., Foldes, F.F. Neuroscience (1989) [Pubmed]
  27. Application of a model to explore interspecies differences in acetylcholine M-receptor-stimulated gastric acid secretion. Welsh, N.J., Shankley, N.P., Black, J.W. Br. J. Pharmacol. (1995) [Pubmed]
  28. M3 and M1 receptors in cerebral arterioles in vivo: evidence for downregulated or ineffective M1 when endothelium is intact. Shimizu, T., Rosenblum, W.I., Nelson, G.H. Am. J. Physiol. (1993) [Pubmed]
  29. M1, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase. Wotta, D.R., Wattenberg, E.V., Langason, R.B., el-Fakahany, E.E. Pharmacology (1998) [Pubmed]
  30. Infralimbic muscarinic M1 receptors modulate anxiety-like behaviour and spontaneous working memory in mice. Wall, P.M., Flinn, J., Messier, C. Psychopharmacology (Berl.) (2001) [Pubmed]
  31. Acetylcholine produces cerebrovascular constriction through activation of muscarinic-1 receptors in the newborn pig. Armstead, W.M., Mirro, R., Leffler, C.W., Busija, D.W. J. Pharmacol. Exp. Ther. (1988) [Pubmed]
  32. Pharmacological studies on surugatoxin, the toxic principle from Japanese ivory mollusc (Babylonia japonica). Hayashi, E., Yamada, S. Br. J. Pharmacol. (1975) [Pubmed]
  33. Effects of McN-A-343 on insect neurosecretory cells: evidence for muscarinic-like receptor subtypes. Lapied, B., Tribut, F., Hue, B. Neurosci. Lett. (1992) [Pubmed]
  34. Inhibition of sympathetic neurotransmission by the opioid delta-receptor agonist DAMA in the pithed rat. Wong-Dusting, H., Rand, M.J. Clin. Exp. Pharmacol. Physiol. (1989) [Pubmed]
  35. Muscarinic receptor subtype in isolated dog and monkey facial vein. Chiba, S., Tsukada, M. Jpn. J. Pharmacol. (1991) [Pubmed]
WikiGenes - Universities